BioSpace: OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

< back

Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically-administered, and targeted oncolytic virus. The company reported positive data in preclinical trials at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020), which concluded November 14th.

To read the full article, click here.